EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae

E B M Breidenstein iD, N Khan, T Duffy, C Coward, T Avis, O Abdulle, C-M Li iD, C S Mason iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00695-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von E B M Breidenstein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Summit Therapeutics, The Works, Unity Campus , Cambridge, United Kingdom. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Enterobacteriaceae (CREs) are described by the Centers for Disease Control as an urgent threat, and there is a critical need for new therapeutic agents able to treat infections caused by these pathogens. Herein, we describe the microbiological profile, the mechanism f action, and the in vitro safety as well as the pharmacokinetic (PK)/PD profile of SMT-738, a small molecule belonging to a new chemical class. SMT-738 is active against Enterobacterales [including multi-drug-resistant Escherichia coli with 90% of isolates having a minimum inhibitory concentration (MIC 90 ) of 1 µg/mL and Klebsiella pneumoniae 2 µg/mL] and inactive against a broad panel of Gram-negative and Gram-positive pathogens. SMT-738 displays rapid bactericidal activity (2–4 h) and has a low propensity for resistance development (less than ~10 −9 ). Characterization of resistant mutants following exposure to SMT-738 identified mutations within the lipoprotein transport complex (LolCDE), a clinically unexploited and essential bacterial molecular target in Gram-negative bacteria. SMT-738 has a promising in vitro toxicology profile. Furthermore, PK studies demonstrated that when dosed intravenously, SMT-738 maintained exposure levels across infection sites (bloodstream/urinary tract/lung). Proof-of-concept studies across multiple murine in vivo infection models (bloodstream/pneumonia/urinary tract) demonstrated that SMT-738 significantly reduced the bacterial burden compared to baseline and vehicle control. SMT-738 represents a promising novel drug candidate being developed to address clinically challenging serious life-threatening infections caused by highly resistant Enterobacteriaceae including CRE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsEnterobacteriaceae InfectionsMiceAnimalsEnterobacteriaceaeGram-Negative BacteriaKlebsiella pneumoniaeLipoproteinsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

SMT-738bacterial lipoprotein transportcarbapenem-resistant Enterobacteriaceae

Substanzen

Anti-Bacterial AgentsLipoproteins

Autor:innen und Institutionen

  • Summit Therapeutics, The Works, Unity Campus , Cambridge, United Kingdom.
  • Summit Therapeutics , Menlo Park, California, USA.

ORCID-Profile: E B M Breidenstein, C-M Li, C S Mason

Förderung

  • Wellcome Trust
  • NIEHS NIH HHS

Zitieren

APA

Breidenstein, E. B. M., Khan, N., Duffy, T., Coward, C., Avis, T., Abdulle, O., Li, C. M., & Mason, C. S. (2024). SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00695-23

Vancouver

Breidenstein EBM, Khan N, Duffy T, Coward C, Avis T, Abdulle O, et al. SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00695-23

BibTeX
@article{Breidenstein2024,
  author = {Breidenstein, E B M and Khan, N and Duffy, T and Coward, C and Avis, T and Abdulle, O and Li, C-M and Mason, C S},
  title = {SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00695-23}
}
Kostenlos starten →